Retatrutide appears to be a new pharmaceutical in the fight against obesity. This revolutionary drug, categorized as a dual GLP-1 and GIP receptor agonist, exhibits promising results in research studies. By boosting these receptors, Retatrutide controls cravings, {promotesenergy expenditure, and ult